PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.

Dinja T KrugerMark OpdamVincent van der NoortJoyce SandersMichiel NieuwenhuisBart de ValkKarin J BeelenSabine C LinnEpie Boven

Published in: Journal of cancer research and clinical oncology (2020)

IHC of single proteins or heatmap subgroups of the differentially activated PI3K/MAPK pathways was not able to discriminate patients on EVE/EXE with poor or better PFS. Upregulation of p-4EBP1 in pre-treatment biopsies as compared to levels in primary tumours pointed towards shorter PFS.

Keyphrases

metastatic breast cancer
end stage renal disease
signaling pathway
newly diagnosed
ejection fraction
chronic kidney disease
poor prognosis
oxidative stress
peritoneal dialysis
cell proliferation
amino acid
small molecule
patient reported outcomes
pi k akt
long non coding rna
smoking cessation